Prostaglandin E2 inhibits eosinophil trafficking through E-prostanoid 2 receptors.
The accumulation of eosinophils in lung tissue is a hallmark of asthma, and it is believed that eosinophils play a crucial pathogenic role in allergic inflammation. Prostaglandin (PG) E(2) exerts anti-inflammatory and bronchoprotective mechanisms in asthma, but the underlying mechanisms have remained unclear. In this study we show that PGE(2) potently inhibits the chemotaxis of purified human eosinophils toward eotaxin, PGD(2), and C5a. Activated monocytes similarly attenuated eosinophil migration, and this was reversed after pretreatment of the monocytes with a cyclooxygenase inhibitor. The selective E-prostanoid (EP) 2 receptor agonist butaprost mimicked the inhibitory effect of PGE(2) on eosinophil migration, whereas an EP2 antagonist completely prevented this effect. Butaprost, and also PGE(2), inhibited the C5a-induced degranulation of eosinophils. Moreover, selective kinase inhibitors revealed that the inhibitory effect of PGE(2) on eosinophil migration depended upon activation of PI3K and protein kinase C, but not cAMP. In animal models, the EP2 agonist butaprost inhibited the rapid mobilization of eosinophils from bone marrow of the in situ perfused guinea pig hind limb and prevented the allergen-induced bronchial accumulation of eosinophils in OVA-sensitized mice. Immunostaining showed that human eosinophils express EP2 receptors and that EP2 receptor expression in the murine lungs is prominent in airway epithelium and, after allergen challenge, in peribronchial infiltrating leukocytes. In summary, these data show that EP2 receptor agonists potently inhibit eosinophil trafficking and activation and might hence be a useful therapeutic option in eosinophilic diseases.
Sturm
Eva M
EM
Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria.
Schratl
Petra
P
Schuligoi
Rufina
R
Konya
Viktoria
V
Sturm
Gunter J
GJ
Lippe
Irmgard Th
IT
Peskar
Bernhard A
BA
Heinemann
Akos
A
D000527:Alprostadil / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D002478:Cells, Cultured; D002634:Chemotaxis, Leukocyte / Q000187:drug effects / Q000276:immunology*; D015232:Dinoprostone / Q000276:immunology* / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004804:Eosinophils / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D006168:Guinea Pigs; D006801:Humans; D007150:Immunohistochemistry; D051379:Mice; D019869:Phosphatidylinositol 3-Kinases / Q000276:immunology / Q000378:metabolism; D011493:Protein Kinase C / Q000276:immunology / Q000378:metabolism; D018078:Receptors, Prostaglandin E / Q000276:immunology* / Q000378:metabolism; D058307:Receptors, Prostaglandin E, EP2 Subtype
D004791:Enzyme Inhibitors; C545644:PTGER2 protein, human; C545645:Ptger2 protein, mouse; D018078:Receptors, Prostaglandin E; D058307:Receptors, Prostaglandin E, EP2 Subtype; D019869:Phosphatidylinositol 3-Kinases; D011493:Protein Kinase C; D000527:Alprostadil; C048491:butaprost; D015232:Dinoprostone